Literature DB >> 25274605

Reliability and extension of quantitative prediction of CYP3A4-mediated drug interactions based on clinical data.

Constance Loue1, Michel Tod.   

Abstract

An approach was proposed in 2007 for quantitative predictions of cytochrome P450 (CYP)3A4-mediated drug-drug interactions. It is based on two characteristic parameters: the contribution ratio (CR; i.e., the fraction of victim drug clearance by CYP) and the inhibition ratio (IR) of the inhibitor. Knowledge of these parameters allows forecasting of the ratio between the area under the plasma concentration-time curve (AUC) of the victim drug when given with the inhibitor and the AUC of the victim drug when it is given alone. So far, these parameters were established for 21 substrates and 17 inhibitors. The goals of our study were to test the assumption of substrate independence of the potency of inhibitors in vivo and to estimate the CR and IR for an extended list of substrates and inhibitors of CYP3A4. The assumption of independence of IRs from the substrate was evaluated on a set of eight victim drugs and eight inhibitors. Forty-four AUC ratios were available. This assumption was rejected in four cases, but it did not result in more than a twofold error in AUC ratio predictions. The extended list of substrates and inhibitors was defined by a thorough literature search. Fifty-nine AUC ratios were available for the global analysis. Final estimates of CRs and IRs were obtained for 37 substrates and 25 inhibitors, respectively. The mean prediction error of the ratios was 0.02, while the mean absolute prediction error was 0.58. Predictive distributions for 917 possible interactions were obtained, giving detailed information on some drugs or inhibitors that have been poorly studied so far.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25274605      PMCID: PMC4389753          DOI: 10.1208/s12248-014-9663-y

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  32 in total

1.  Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.

Authors:  Eleanor J Guest; Karen Rowland-Yeo; Amin Rostami-Hodjegan; Geoffrey T Tucker; J Brian Houston; Aleksandra Galetin
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

2.  Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions.

Authors:  Michel Tod; Sylvain Goutelle; Fannie Clavel-Grabit; Grégoire Nicolas; Bruno Charpiat
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

3.  Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation.

Authors:  Robert S Foti; Dan A Rock; Larry C Wienkers; Jan L Wahlstrom
Journal:  Drug Metab Dispos       Date:  2010-03-04       Impact factor: 3.922

4.  Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.

Authors:  Brian J Kirby; Ann C Collier; Evan D Kharasch; Dale Whittington; Kenneth E Thummel; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2011-03-15       Impact factor: 3.922

5.  General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.

Authors:  Yoshiyuki Ohno; Akihiro Hisaka; Masaki Ueno; Hiroshi Suzuki
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 6.  Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.

Authors:  Shu-Feng Zhou
Journal:  Curr Drug Metab       Date:  2008-05       Impact factor: 3.731

7.  General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.

Authors:  Yoshiyuki Ohno; Akihiro Hisaka; Hiroshi Suzuki
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis.

Authors:  Isabelle Ragueneau-Majlessi; Xavier Boulenc; Clemence Rauch; Houda Hachad; René H Levy
Journal:  Curr Drug Metab       Date:  2007-12       Impact factor: 3.731

9.  Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects.

Authors:  Ping Liu; Grover Foster; Kuan Gandelman; Robert R LaBadie; Mark J Allison; Maria J Gutierrez; Amarnath Sharma
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

Review 10.  Colchicine for pericarditis: hype or hope?

Authors:  Massimo Imazio; Antonio Brucato; Rita Trinchero; David Spodick; Yehuda Adler
Journal:  Eur Heart J       Date:  2009-02-03       Impact factor: 29.983

View more
  12 in total

1.  A Model for Predicting the Interindividual Variability of Drug-Drug Interactions.

Authors:  M Tod; L Bourguignon; N Bleyzac; S Goutelle
Journal:  AAPS J       Date:  2016-12-06       Impact factor: 4.009

2.  A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4.

Authors:  Michel Tod; S Goutelle; N Bleyzac; L Bourguignon
Journal:  Clin Pharmacokinet       Date:  2019-04       Impact factor: 6.447

3.  Identification of Cytochrome P450-Mediated Drug-Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model.

Authors:  Nicolas Fermier; Laurent Bourguignon; Sylvain Goutelle; Nathalie Bleyzac; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

4.  A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.

Authors:  Julie Steelandt; Elodie Jean-Bart; Sylvain Goutelle; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

5.  Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo.

Authors:  Roland Heinig; Michael Gerisch; Anna Engelen; Johannes Nagelschmitz; Stephanie Loewen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-12       Impact factor: 2.441

6.  Semi-Mechanistic Model for Predicting the Dosing Rate in Children and Neonates for Drugs Mainly Eliminated by Cytochrome Metabolism.

Authors:  Lena Cerruti; Nathalie Bleyzac; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2018-07       Impact factor: 6.447

7.  Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors.

Authors:  Camille Azam; Pauline Claraz; Christine Chevreau; Camille Vinson; Ewa Cottura; Loïc Mourey; Damien Pouessel; Selena Guibaud; Olivia Pollet; Magali Le Goff; Catherine Bardies; Véronique Pelagatti; Jean Marie Canonge; Florent Puisset
Journal:  Eur J Clin Pharmacol       Date:  2020-01-13       Impact factor: 2.953

8.  Quantitative Prediction of Interactions Mediated by Transporters and Cytochromes: Application to Organic Anion Transporting Polypeptides, Breast Cancer Resistance Protein and Cytochrome 2C8.

Authors:  Michel Tod; Laurent Bourguignon; Nathalie Bleyzac; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

9.  Evaluation of the inhibition potential of plumbagin against cytochrome P450 using LC-MS/MS and cocktail approach.

Authors:  Ang Chen; Xiaojing Zhou; Shuowen Tang; Mingyao Liu; Xin Wang
Journal:  Sci Rep       Date:  2016-06-22       Impact factor: 4.379

10.  Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile.

Authors:  Vianney Tuloup; Mathilde France; Romain Garreau; Nathalie Bleyzac; Laurent Bourguignon; Michel Tod; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.